COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX: CLN) today is providing an update to its SPA application for Primary Liver Cancer. As previously reported, the FDA requested and received an update to the study’s Radiology Charter. Although the FDA could take an additional 45 days from the time of receipt to issue a formal response, at that time Celsion was advised that the submission would be acted upon within a week to ten days. Subsequently, the FDA has advised the company that the review is still in progress, but did not indicate a definitive date for the agency’s issuance of the formal response.
